NAVB - Navidea Biopharmaceuticals, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
1.3400
-0.0400 (-2.90%)
As of 11:04AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.3800
Open1.3800
Bid0.0000 x 1000
Ask0.0000 x 1000
Day's Range1.3203 - 1.3507
52 Week Range0.4900 - 4.2000
Volume33,661
Avg. Volume643,654
Market Cap23.544M
Beta (5Y Monthly)0.90
PE Ratio (TTM)N/A
EPS (TTM)-0.9300
Earnings DateNov 06, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.50
  • Business Wire

    Navidea Biopharmaceuticals Obtains Partial Dismissal of Claims in New York

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on December 26, 2019, the United States District Court, Southern District of New York (the "Court") ruled on several motions related to Navidea and its majority-owned subsidiary, Macrophage Therapeutics, Inc. ("MT") and Dr. Michael Goldberg that substantially limited the claims that Dr. Goldberg can pursue against Navidea and MT.

  • The  of Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB), John Scott, Just Bought 11% More Shares
    Simply Wall St.

    The of Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB), John Scott, Just Bought 11% More Shares

    Investors who take an interest in Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) should definitely note that insider...

  • Business Wire

    Navidea Biopharmaceuticals Announces $1.9 Million Private Placement

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that they have executed agreements with five investors, including an existing investor, John K. Scott, Jr. (collectively, the "Investors"), to purchase approximately 2.1 million shares of the Company’s common stock, par value $0.001 per share, in a private placement for aggregate gross proceeds to Navidea of approximately $1.9 million. The securities to be issued to the Investors will represent approximately 9.3% of the Company’s outstanding common stock after such issuance.

  • Business Wire

    Navidea Biopharmaceuticals to Present at the 12th Annual LD Micro Main Event

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Mr. Jed Latkin, Chief Executive Officer, will present at the 12th Annual LD Micro Main Event investor conference. The conference will be held at the Luxe Bel Air Hotel in Los Angeles, CA on December 10-12, 2019. Mr. Latkin will present on Wednesday, December 11 at 10:20 a.m. PT (1:20 p.m. ET) in Track 4, which will be webcast.

  • Business Wire

    Navidea Biopharmaceuticals Wins Summary Judgment in Ohio

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Court of Common Pleas for Franklin County, Ohio (the “Ohio Court”) issued a ruling in favor of Navidea in its case against Capital Royalty Partners II, L.P., et al (“CRG”). As disclosed in the Company’s 2018 Annual Report on Form 10-K and other regulatory filings, the Company has been engaged in ongoing litigation with CRG, in its capacity as a lender and as control agent for other affiliated lenders party to the CRG Loan Agreement (collectively, the “Lenders”) in the Ohio Court related to Navidea’s claims that the Lenders fraudulently induced Navidea to enter into a settlement agreement and breached the terms of the same through certain actions taken by the Lenders in connection with the Global Settlement Agreement reached in 2017, pursuant to which Navidea agreed to pay up to $66.0 million to Lenders, as well as through actions and misrepresentations by CRG after the Global Settlement Agreement was executed.

  • Thomson Reuters StreetEvents

    Edited Transcript of NAVB earnings conference call or presentation 7-Nov-19 10:00pm GMT

    Q3 2019 Navidea Biopharmaceuticals Inc Earnings Call

  • Business Wire

    Navidea Biopharmaceuticals to Present at the PCG Spotlight Series Conference

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it will present at the PCG Spotlight Series Conference taking place on Thursday, November 21st at the Harvard Club, 35 West 44th Street, New York, NY at 12:25pm ET. Mr. Jed A. Latkin, Chief Executive Officer, will be presenting and meeting with investors throughout the conference. “We look forward to presenting our clinical programs at the PCG Spotlight Series Conference,” commented Jed A. Latkin, Chief Executive Officer of Navidea.

  • What Kind Of Shareholders Own Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB)?
    Simply Wall St.

    What Kind Of Shareholders Own Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB)?

    If you want to know who really controls Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB), then you'll have to look at...

  • Business Wire

    Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial Results

    Conference Call to be held Thursday, November 7, 2019 at 5:00 pm EDT

  • Business Wire

    Navidea Biopharmaceuticals Announces Preclinical Therapeutic Research Collaboration with IMV Inc. to Explore the Potential Combinatory Effect with Their Platform-Based Immunotherapies

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB), a company focused on the development of precision immunodiagnostics and immunotherapeutics, and IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, have entered a preclinical research collaboration to explore the potential combinatory effect of their platform-based immunotherapies. The purpose of this collaboration is to conduct preclinical studies to evaluate the combinatory effect of Navidea’s proprietary activated macrophage targeting therapeutics along with IMV’s DPX-based immunotherapies.

  • Business Wire

    Navidea Biopharmaceuticals to Host Third Quarter 2019 Earnings Conference Call and Corporate Update

    Conference Call to be held Thursday, November 7, 2019 at 5:00 p.m.

  • Business Wire

    Navidea Biopharmaceuticals Announces Positive Results of First Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce positive results from the Company’s first interim analysis of its ongoing NAV3-31 Phase 2B study. Analysis demonstrates that these interim data support Navidea’s hypotheses that Tc 99m Tilmanocept imaging can provide robust, quantitative imaging in healthy controls and in patients with active rheumatoid arthritis (“RA”) and that this imaging is stable, reproducible, and can define joints with and without RA-involved inflammation. Navidea’s NAV3-31 Phase 2B trial titled “Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging” has three arms: Arm 1 consists of healthy subjects, Arm 2 is comprised of patients with active, moderate-to-severe rheumatoid arthritis (RA) who are on stable therapy, and Arm 3 is a pilot arm of the upcoming Phase 3 trial assessing the ability of Tc 99m tilmanocept to provide an early indicator of efficacy of anti-TNF alpha treatment in RA patients.

  • Thomson Reuters StreetEvents

    Edited Transcript of NAVB earnings conference call or presentation 8-Aug-19 9:00pm GMT

    Q2 2019 Navidea Biopharmaceuticals Inc Earnings Call

  • Business Wire

    Navidea Biopharmaceuticals Announces SNMMI Press Release and Recognition of Phase 1/2 Study Results

    Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the results of the Company’s NAV3-21 clinical study at the Society of Nuclear Medicine and Molecular Imaging (“SNMMI”) Annual Meeting in Anaheim, CA have been highlighted with a press release by the SNMMI (http://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=31987). The presentation, titled “A Phase I/Phase II Study of Intravenously (“IV”) Administered Tc99m Tilmanocept (“TCT”) to Determine Safety, Tolerability, Optimal Clinical Dose Selection, and Imaging Timepoint in Patients Clinically Diagnosed with Rheumatoid Arthritis (“RA”)" was delivered at the Society’s Annual Meeting on Sunday, June 23, 2019 by Arash Kardan, M.D. In addition, an abstract of the presentation will be published in a future edition of the Journal of Nuclear Medicine.

  • Business Wire

    Navidea Biopharmaceuticals Announces Closing of Public Offering of Common Stock

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the closing of an underwritten public offering of 8,000,000 shares of its common stock, at a price to the public of $0.75 per share. Of the total shares sold in the offering, 4,000,000 shares were placed with John Kim Scott, Jr., a principal stockholder in the Company, who agreed to purchase such shares at a purchase price of $0.75 per share.

  • Thomson Reuters StreetEvents

    Edited Transcript of NAVB earnings conference call or presentation 8-May-19 9:00pm GMT

    Q1 2019 Navidea Biopharmaceuticals Inc Earnings Call

  • Business Wire

    Navidea Biopharmaceuticals Announces Day and Time of SNMMI Presentation of Phase 1/2 Study Results and Enrollment Update on its Phase 2B Study

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce the details of an oral presentation on the results of the Company’s NAV3-21 clinical study at the Society of Nuclear Medicine and Molecular Imaging (“SNMMI”) Annual Meeting in Anaheim, CA. The presentation, titled “A Phase I/Phase II Study of Intravenously (“IV”) Administered Tc99m Tilmanocept (“TCT”) to Determine Safety, Tolerability, Optimal Clinical Dose Selection, and Imaging Timepoint in Patients Clinically Diagnosed with Rheumatoid Arthritis (“RA”)" will be delivered at 12:30 PM, Sunday, June 23, 2019 by Arash Kardan, M.D. In addition, an abstract of the presentation will be published in a future edition of the Journal of Nuclear Medicine.

  • Business Wire

    Navidea Biopharmaceuticals Prices $6.0 Million Public Offering of Common Stock

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the pricing of its previously announced underwritten public offering of 8,000,000 shares of common stock at a price to the public of $0.75 per share. Navidea has also granted the underwriter a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

  • Business Wire

    Navidea Biopharmaceuticals Announces Proposed Public Offering of Common Stock

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Navidea also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock to be sold in the offering at the public offering price, less underwriting discounts and commissions in such underwritten offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • Business Wire

    Navidea Biopharmaceuticals Regains Direct Control of Intellectual Property

    On June 12, 2019, Vice Chancellor Joseph Slights of the Court of Chancery of the State of Delaware issued an oral ruling granting the motion of Macrophage Therapeutics, Inc. (“MT”), a subsidiary of Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), to declare as void certain transactions putatively authorized by MT’s former Chief Executive Officer, Dr. Michael Goldberg (“Dr. Goldberg”), pursuant to which Dr. Goldberg purported to transfer certain of Navidea’s intellectual property rights (which had been assigned to MT) to a company controlled by Dr. Goldberg.

  • Associated Press

    Navidea: 1Q Earnings Snapshot

    On a per-share basis, the Dublin, Ohio-based company said it had a loss of 24 cents. The biopharmaceutical posted revenue of $136,000 in the period. In the final minutes of trading on Wednesday, the company's ...